Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Hydroxyurea and Transfusion
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Children's National Research Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03644953
- Locations
- 🇺🇸
Children's National Health System, Washington, District of Columbia, United States
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-05-22
- Target Recruit Count
- 60
- Registration Number
- NCT03515018
- Locations
- 🇨🇳
the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03500731
- Locations
- 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- M.E. van Linde
- Target Recruit Count
- 54
- Registration Number
- NCT03463733
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Conditions
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 80
- Registration Number
- NCT03263559
- Locations
- 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States
The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Dr.Saqib Hussain Ansari
- Target Recruit Count
- 100
- Registration Number
- NCT03183375
- Locations
- 🇵🇰
Omair Sana Foundation, Karachi, Sindh, Pakistan
Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 187
- Registration Number
- NCT03128515
- Locations
- 🇺🇬
Mulago Hospital Sickle Cell Clinic, Kampala, Uganda
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 76
- Registration Number
- NCT03107182
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 57
- Registration Number
- NCT03077542
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.